The STAT podcast episode highlights Retro Biosciences' upcoming clinical readout and Sam Altman's backing, alongside concerns over Chinese competition in biotech. Yet mainstream coverage misses the deeper pattern: U.S. national-security policies on tech transfer are colliding with unprecedented private capital inflows into longevity, a field where peer-reviewed evidence remains thin. Observational studies on hallmarks of aging (e.g., López-Otín et al., Cell 2013, n=~200 model organisms) dominate, while true RCTs are scarce—most longevity trials involve under 500 participants and carry industry conflicts. Retro's AI-drug efforts echo this: no large-scale RCT data yet exists for AI-accelerated senolytics. U.S. export controls and CFIUS scrutiny, intensified since 2022, now target biotech deals, potentially slowing capital to firms like Retro while Chinese state-backed entities accelerate parallel programs. This intersection risks politicizing wellness innovations without demanding rigorous evidence, a gap the original reporting overlooks.